Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I trial of the alpha particle-emitting radiopharmaceutical, af-001, in patients with differentiated thyroid cancer (papillary carcinoma, follicular carcinoma)

Trial Profile

A Phase I trial of the alpha particle-emitting radiopharmaceutical, af-001, in patients with differentiated thyroid cancer (papillary carcinoma, follicular carcinoma)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Af 001 (Primary)
  • Indications Thyroid cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Alpha Fusion

Most Recent Events

  • 27 Nov 2025 New trial record
  • 31 Oct 2025 According to Alpha Fusion media release, this clinical trial is designed based on the results of an investigator-initiated Phase I study conducted at The University of Osaka.
  • 31 Oct 2025 According to an Alpha Fusion media release, Part Ia of the study will be conducted at the National Cancer Center Hospital East (Principal Investigator: Dr. Makoto Tahara, Chief, Department of Head and Neck Medical Oncology), and Part Ib will be conducted at multiple sites in Japan.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top